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Abstract
The set of peptides presented on a cell’s surface by MHC molecules is known as the immunopeptidome. Current
mass spectrometry technologies allow for identification of large peptidomes, and studies have proven these data to
be a rich source of information for learning the rules of MHC-mediated antigen presentation. Immunopeptidomes
are  usually  poly-specific,  containing  multiple  sequence  motifs  matching  the  MHC molecules  expressed  in  the
system under investigation. Motif  deconvolution -the process  of associating each ligand to its  presenting MHC
molecule(s)- is therefore a critical and challenging step in the analysis of MS-eluted MHC ligand data.  Here, we
describe NNAlign_MA, a computational method designed to address this challenge and fully benefit from large,
poly-specific  data  sets  of  MS-eluted  ligands.  NNAlign_MA simultaneously  performs  the  tasks  of  i)  clustering
peptides into individual specificities; ii) automatic annotation of each cluster to an MHC molecule; and iii) training
of a prediction model covering all MHCs present in the training set. NNAlign_MA was benchmarked on large and
diverse datasets, covering class I and class II data. In all cases, the method was demonstrated to outperform state-of-
the-art methods, effectively expanding the coverage of alleles for which accurate predictions can be made, resulting
in improved identification of both eluted ligands and T cell epitopes. Given its high flexibility and ease of use, we
expect  NNAlign_MA to serve  as an effective  tool to  increase  our understanding of  the rules  of  MHC antigen
presentation and guide the development of novel T cell-based therapeutics. 
Introduction
Major Histocompatibility Complex (MHC) molecules play a central  role in the cellular immune system as cell-
surface presenters of antigenic peptides to T cell receptors (TCR). Upon presentation, the peptide-MHC complex
(pMHC) is scrutinized by T cells and an immune response can be initiated if interactions between the pMHC and
TCR are established. 
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The collection of peptides presented by MHC molecules is referred to as the immunopeptidome. Because of the
extreme polymorphism of the MHC, immunopeptidomes can vary dramatically within a population, contributing to
the personalized attributes of the vertebrate immune system. 
Due  to  the  essential  role  of  the  MHC  in  defining  immune  responses,  large  efforts  have  been  dedicated  to
understanding the rules that shape the immunopeptidome, as well as its alterations in disease – either as a result of
pathogen  infection  or  cancerous  mutation (1).  A  crucial  step  towards  defining  the  immunopeptidome  of an
individual is the characterization of the binding preferences of MHC molecules. The peptide-binding domain of
MHC molecules consists of a groove, with specific amino acid preferences at different positions. MHC class I, by
and large, loads peptides between eight and thirteen residues  long (2,  3). MHC class II molecules have an open
binding groove at both ends and can bind much longer peptides, and even whole proteins (4, 5).
Peptide-MHC binding affinity (BA) assays represented the first attempts of studying binding preferences of different
MHC  molecules  in  vitro (6,  7).  However,  BA  characterization  ignores  many  in  vivo antigen  processing  and
presentation features, such as protein internalization, protease digestion, peptide transport, peptide trimming, and the
role of different chaperones involved in the folding of the pMHC complex (8). Further, BA assays most often are
conducted one peptide at a time, thus becoming costly, time-consuming, and low-throughput. 
Recently, advances in liquid chromatography mass spectrometry (in short, LC-MS/MS) technologies have opened a
new chapter in immunopeptidomics. Several thousands of MHC-associated eluted ligands (in short, EL) can with
this technique be sequenced in a single experiment (9) and numerous assessments have proven MS EL data to be a
rich source of information for both rational identification of T cell epitopes (10, 11) and learning the rules of MHC
antigen presentation (12, 13).
In this context, we have demonstrated how a modeling framework that integrates both BA and EL data achieves
superior predictive performance for T cell epitope discovery compared to models trained on either of the two data
types alone (13,  14). In these studies, the modeling framework was an improved version of the NNAlign method
(15), which incorporated two output neurons to enable training and prediction on both BA and EL data types. In this
setup,  weight-sharing  allows  information  to  be  transferred  between  the  two data  types  resulting  in  a  boost  in
predictive power. For MHC class I, we have demonstrated how this framework can be extended to a pan-specific
model,  capturing the specific  antigen presentation  rules  for  any  MHC molecule  with known protein  sequence,
including molecules characterized by limited, or even no, binding data (14, 16, 17).
Except genetically engineered cells, all nucleated cells express multiple MHC-I alleles and all antigen presenting
cells additionally express multiple MHC-II alleles on their surface.  The antibodies used to purify peptide-MHC
complexes in MS EL experiments are mostly pan- or locus-specific, and the data generated in an MS experiment are
thus inherently poly-specific  –  i.e.  they  contain ligands matching multiple binding motifs.  For instance,  in  the
context of the human immune system, each cell can express up to six different MHC class I molecules, and the
immunopeptidome obtained using MS techniques will thus be a mixture of all ligands presented by these  MHCs
(12). The poly-specific nature of MS EL libraries constitutes a challenge in terms of data analysis and interpretation,
where,  in order to learn specific MHC rules for antigen presentation, one must first associate each ligand to its
presenting MHC molecule(s) within the haplotype of the cell line.
Several approaches have been suggested to address this task, including experimental setups that employ cell lines
expressing only one specific MHC molecule (10,  18–20), and approaches inferring MHC associations using prior
knowledge  of  MHC  specificities (21) or  by  means  of  unsupervised  sequence  clustering (22).  For  instance,
GibbsCluster (23, 24) has been successfully employed in multiple studies to extract binding motifs from EL datasets
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of several species, both for MHC class I and MHC class II (5,  25–27). A similar tool,  MixMHCp (22) has been
applied to the deconvolution of MHC class I EL data with performance comparable to GibbsCluster.
However, neither of these methods are able to fully deconvolute the complete number of MHC specificities present
in each dataset, especially for cell lines containing overlapping binding motifs and/or lowly expressed molecules (as
in the case of HLA-C). Moreover, for both methods the association of each of the clustered solutions to a specific
HLA molecule must be guided by prior knowledge of the MHC binding motifs, for instance by recurring to MHC-
peptide  binding  predictions (16).  Therefore,  both  methods  require  some  degree  of  manual  intervention  for
deconvolution and allele annotation.
A recently published method was suggested to overcome this limitation. The computational framework by Bassani-
Sternberg et al. (28) employs MixMHCp (22) to generate peptide clusters and binding motifs for a panel of poly-
specificity MS datasets, and next links each cluster to an HLA molecule based on allele co-occurrence and exclusion
principles. While this approach constitutes a substantial step forward for aiding the interpretation of MS EL data, it
is clear that it has some substantial shortcomings. First and foremost, the success of the method is tied to the ability
of MixMHCp to identify all the binding motifs in a given MS dataset, an ability that is challenged in particular for
cell lines containing MHC alleles with similar binding motifs, and for molecules characterized by low expression
levels (22, 29). Secondly, successful HLA labeling of the obtained clusters is limited by allele co-occurrences and
exclusions across multiple cell line datasets. While one may argue that this shortcoming is destined to wane as more
immunopeptidomics datasets are accumulated in public databases, there currently remain multiple cases when co-
occurrence and exclusion principles fail to completely deconvolute peptidome specificities (28).
Inspired by the framework outlined by Bassani-Sternberg et al.  (28) and by the earlier success of the pan-specific
NNAlign framework for modeling peptide-MHC binding (14), we here present a novel machine learning algorithm
resolving these shortcomings, enabling a fully automated clustering and labeling of MS EL data. The algorithm is an
extension of the NNAlign neural network  framework (15,  30,  31), and is capable of taking a mixed training set
composed of single-allele (SA) data (peptides assigned to single MHCs) and multi-allele (MA) data (peptides with
multiple  options  for  MHCs  assignments)  as  input  and  deconvolute  the  individual  MHC restriction  of  all  MA
peptides while learning the binding specificities of all the MHCs present in the training set. Compared to earlier
approaches for  peptidome deconvolution, annotation, and prediction model training (e.g.  GibbsCluster/NNAlign
(29) and MixMHCp/MixMHCpred (28)), NNAlign_MA performs these three tasks simultaneously, by iteratively
updating the clustering, MHC annotation and peptide binding predictions in an integrated framework. NNAlign_MA
does not require manual curation to assign the correct number of clusters, nor for the annotation of clusters to their
respective MHC molecule. NNAlign_MA is available at: 
www.cbs.dtu.dk/suppl/immunology/NNAlign_MA/NNAlign_MA_testsuite.tar.gz.
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Materials and Methods
Peptide data
Several types of MHC peptide data for human (HLA) and bovine (BoLA) class I, and HLA class II were gathered to
train the predictive models presented in this work. Peptide data was classified as single allele data (SA, where each
peptide is  associated to a single MHC restriction) and multi  allele  data (MA, where each  peptide has multiple
options for MHC restriction). MA data are generated from MS MHC ligand elution assays where most often a pan-
specific antibody is applied for class I and either a pan-specific class II or a pan-DR specific antibody is applied for
class II in the immuno-precipitation step leading to datasets with poly-specificities matching the MHC molecules
expressed  in  the  cell  line  under  study.  SA  data  were  obtained  from  binding  affinity  assays,  or  from  mass
spectrometry experiments performed using genetically engineered cell lines that artificially express one single allele.
HLA class I: SA data - both binding affinity (BA), and MS MHC eluted ligands (EL) - was extracted from Jurtz et
al. (14). The MA data was collected from eight different sources (12, 25, 26, 28, 32–35). Both datasets were filtered
to include only peptides of length 8-14 amino acids. Additional information concerning the HLA class I MA data
can be found in Supplementary Table 1 and information concerning the SA BA and EL data sets in Supplementary
Table 2.
HLA-II: BA data was extracted from the NetMHCIIpan-3.2 publication (36). As for EL data, the Immune Epitope
Database (37) (IEDB) was queried to identify publications with a large number of allele annotated EL data, both SA
and MA (27, 38–45). Ligands were extracted from these publications, excluding any ligands with post translational
modifications. Both BA and EL data was length filtered  to include only peptides of length 13-21. Details on the
composition of the HLA class II MA data are shown in Supplementary Table 3.
Regarding BoLA, SA data was extracted from Nielsen et al. (16) and the MA data was collected either from the
same publication (data for the MHC homozygous cell lines expressing the haplotypes A10, A14, A18) or were
generated for this study (data for the cell lines expressing the haplotypes A11/A11, A19/A19, A20/A20, A15/A15,
and A12/A15). All datasets were filtered to include only peptides of length 8-14. A summary of the BoLA MA data
is given in Supplementary Table 4.
BoLA EL data generated for this study
BoLA Cell Lines and BoLA-I-Associated Peptide Purification: BoLA Cell Lines and BoLA-I-Associated Peptide
Purification were performed according to the procedures described in (16).
LC–MS2 Analysis: Samples were suspended in 20 μL of loading buffer (1% acetonitrile, 0.1% TFA in water) and 
analyzed on an Ultimate 3000 nano UPLC system online coupled to a Fusion Lumos mass spectrometer (Thermo 
Scientific). Peptides were separated on a 75 μm × 50 cm PepMap C18 column using a 1h linear gradient from 5 to 
25% buffer B in buffer A at a flow rate of 250 nL/min (∼600 bar). Peptides were introduced into the mass 
spectrometer using a nano Easy Spray source (Thermo Scientific) at 2000V and ion transfer tube temperature of 
305°C. Subsequent isolation and higher energy C-trap dissociation (HCD) was induced on the most abundant ions 
per full MS scan at 2s cycle time. Ions with a charge of 2-4 were measured at an accumulation time of 120 ms, AGC
target of 200,000, quadrupole isolation width of 1.2 Da, and energy level 28. All fragmented precursor ions were 
actively excluded from repeated selection for 60 s. The mass spectrometry proteomics data have been deposited to 
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the ProteomeXchange Consortium via the PRIDE (46) partner repository with the dataset identifier PXD015240 and
10.6019/PXD015240.
MS Data Analysis: MS data was searched against a database comprising the 23/12/2017 download Uniprot entries
for organism bos bovis (32,207 entries) concatenated with 4,084 Theileria muguga protein sequences annotated from
RNAseq data of the schizont stage of  T. parva (GenBank, BioSample accession SAMN03981746) plus a single
entry for beta-galactosidase of E. coli. 36,692 entries were searched simultaneously in Peaks v8.5. No specificity
was set for enzymatic digestion and no modifications of amino acids allowed. Mass tolerance for precursor ions was
5 ppm, while fragment mass tolerance was set to 0.03 Da. Score threshold was set corresponding to a false discovery
rate of 1.0% as determined by simultaneous decoy database searches integrated in the Peaks 8.5 software. The full
list  of  MS  identified  peptides  generated  for  this  work  can  be  found  in  the  supplementary  file
Full_BoLA_MS_data.xlsx.
Training data
Three training sets were constructed, one for each of the systems under study (Table 1). To ensure an unbiased
performance evaluation on the MA data, duplicated entries between the SA EL and MA data were first removed
from the SA EL dataset for each training set. Next, random peptides were extracted from the UniProt database and
used as negative instances for the EL data in each case. Here, an equal amount of random negatives was used for
each length, consisting of five times the amount of peptides for the most abundant length in the given positive EL
dataset as described earlier (13,  16). This enrichment with random natural negative peptides was done for each
individual SA and MA EL dataset. The amount of positive and negative peptides in each training set is shown in
Table 1.
Table 1. Training data overview.
SA (BA) SA (EL) MA (EL)
Pos Neg # MHCs Pos Negs # MHCs Pos Neg # MHCs Len
HLA-I 50,344 127,169 104 46,183 740,939 51 225,751 5,399,788 67 8-14
BoLA-I 50,361 150,833 7 84,717 1,644,976 - 92,339 1,788,293 16 8-14
HLA-II 55,178 76,185 59 32,510 337,720 8 15,494 152,445 16 13-21
For each MHC system (first column), the number of positive and negative instances is shown for each type of
training data. SA: Single Allele; MA: Multi Allele; BA: Binding Affinity; EL: Eluted Ligands. 
Evaluation data
For HLA class I, an independent evaluation data set of HLA restricted CD8+ epitopes was obtained from Jurtz et al.
(14). After removal of epitopes overlapping with the HLA-I training data, the final evaluation data consisted of 558
HLA-epitope entries. 
For  the  evaluation  with  MixMHCpred,  MHCFlurry,  and  MHCFlurry_EL  (the  version  of  MHCFLurry  trained
including EL data), the epitope data set was further filtered to only include epitopes restricted to HLA molecules
covered by all method. This resulted in a data set of 541 epitopes. Since MixMHCpred cannot make predictions for
peptides containing X, all such peptides were removed from the benchmark prior to evaluation. 
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For BoLA-I, a set of BoLA restricted epitopes were obtained from Nielsen et al. (16). For HLA-I and BoLA-I
evaluation, the source protein sequence of each epitope was in-silico digested into overlapping 8-14mers, and the
performance reported as the Frank score, i.e. proportion of peptides with a prediction score higher than that of the
epitope (14). Using this measure, a value of 0 corresponds to a perfect prediction (the known epitope is identified
with the highest predicted binding value among all peptides found within the source protein) and a value of 0.5 to
random prediction.
For HLA class II all CD4+ epitopes measured by Intracellular Cytokine Staining(ICS) assay were downloaded from
the IEDB. The set was filtered to include only positive epitopes with four letter resolution HLA typing. Furthermore,
epitopes overlapping with the HLA-II training data (100% identity) were removed. As for HLA-I, the Frank was
used to validate the model performance, here in-silico digesting the source protein into overlapping of a length equal
to that of the epitope. Finally, to exclude potential noise, epitopes were discarded if none of the predictions methods
included in the benchmark could identify the epitope with a Frank value of 0.2 or less. This resulted in a set of 221
HLA-II epitopes for evaluation. 
NNAlign_MA modeling and training hyperparameters
Models for peptide-MHC binding prediction were trained with hyperparameters and model architectures similar to
those described earlier (13, 15, 29) for prediction of peptide-MHC binding based on the datasets described in Table
1. Positive instances in EL datasets (for both SA and MA) were labeled with a target value of 1, and negatives with a
target value of 0. 
In order to avoid performance overestimation and model overfitting, training sets were split into 5 partitions for
cross-validation purposes using the common motif algorithm (47) with a motif length of 8 amino acids for class I
(corresponding to the shortest binding mode for class I peptides) and 9 amino acids for class II (corresponding to the
size of the class II binding core) as described earlier (13, 14).
A single and simple yet highly critical step sets the updated NNAlign_MA method proposed here aside from its
ancestors. To be able to accurately handle and annotate MA data, NNAlign_MA imposes a burn-in period where the
method is trained only on SA data. After the burn-in period, each data point in the MA dataset is annotated by
predicting binding to all possible MHC molecules defined in the MA dataset, and assigning the restriction from the
highest prediction value (see the Prediction score rescaling section for variations on this). After this annotation step,
the SA and MA data are merged respecting the data partitioning to further train the algorithm. This MA annotation
step is repeated in each training cycle.
In the case of HLA-I and BoLA-I, models were trained on the full set of SA and MA data as an ensemble of 50
individual  networks,  generated  from 5  different  seeds;  56  and  66  hidden  neurons;  and  5  partitions  for  cross-
validation. Models were trained for 200 iterations (using early stopping), with a burn-in period of 20 iterations. For
performance comparison, a SA-only model was trained for HLA-I using the same architecture and hyper-parameters
by excluding all MA data from the cross-validation partitions, thus including only data for SA while respecting the
training data structure. 
Regarding HLA-II, default settings for MHC-II prediction as previously described (13, 29) were used. Models were
trained and evaluated on 5-fold cross-validation partitions defined by common motif clustering with a motif of
length 9. The final ensemble of models consists of 250 networks (2, 10, 20, 40 and 60 hidden neurons and 10
random weight initiation seeds for each CV fold). Networks were trained for 400 iterations, without early stopping
and using a burn-in period of 20.
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All networks have an input layer, a single hidden layer and an output layer with two output values (one for binding
affinity  and  one  for  eluted  ligand  likelihood).  Networks  were  trained  using  back-propagation  with  stochastic
gradient descent  and a fixed learning rate of 0.05. When making predictions using the network ensembles,  the
average over the individual network predictions was used. 
Prediction score rescaling
To level out differences in the prediction scores between MHC alleles imposed by the differences in number of
positive training examples  and distance  to the training data included in the SA dataset,  a rescaling of  the raw
prediction values was implemented and applied in the MA data annotation. The rescaling was implemented as a z-
score transformation of the raw prediction values using the relation z=( p− p¯ ) /σ , where p is the raw prediction
value of the peptide to a given MHC molecules, and p¯ and σ  are the mean and standard deviation of the distribution
of prediction values for random natural peptides for the MHC molecule. Here, the score distribution was estimated
by predicting binding of 10,000 random natural 9mer peptides to MHC molecule in question. Next, the mean and
standard deviation were estimated from a positive normal distribution, iteratively excluding outliers (z-score < -3 or
z-score  >  3).  For  an  example  on  how  z-score  is  applied  to  transform  prediction  score  distributions,  see
Supplementary Figure 6. This estimation of  p¯ and σ  was repeated in each iteration round prior to annotating the
MA data. As the rescaling is imposed to level out score differences between MHC molecules characterized in the
SA training binding data and molecules from the MA data distant to the training data, the need for rescaling should
be leveled out as the MA data are included in the training and the NNAlign_MA training progresses. To achieve
this, the values of p¯ and σ  were modified to converge towards uniform values p¯u and σ u defined as the average of
p¯ and  σ  over all molecules in the MA dataset. This convergence was defined as  p¯ '=w∗ p¯+ (1−w )∗ p¯u and
σ '=w∗σ+(1−w )∗σu,  where  w=1/ (1+e ( x− 75) /10 ) and  x is  the  number  of  training  iterations.  With  this
relation, when w  is close to 1 after pre-training (x = 20), the terms p¯u and σ u vanish; on the other hand, as x passes
100 iterations, w converges to 0 and the terms p¯ and σ  will vanish. With this, one can modulate the rescaling of the
data as a function of the iterations and the type of data being used for training (SA or MA). The shift value of the
exponential present in  w  (75) is a tunable parameter that defines this adjustment schedule. Similar results as the
ones shown in this work were obtained varying this value in the range 50-100 (data not shown).
Distance between pairs of MHC molecules
The distance between MHC molecules was calculated as described earlier (48) from the sequence similarity between
the pseudo sequences of the two molecules. Likewise, was the distance of an MHC molecule to the data used to train
a given prediction model, defined as the closest distance to any MHC molecule included in the training data.
Pruning the HLA supertype tree - HLA models with removed 
specificities
In order to quantify how MA data can boost the performance of a peptide-MHC predictor, we constructed additional
models, where SA data associated with HLA molecules from the A2 and A3 supertypes where exclude from the
training data. In short, this was achieved by first identifying the alleles in the MA data for the two supertypes (49),
resulting in the following allele list: HLA-A*02:01, HLA-A*02:05, HLA-A*02:06, HLA-A*02:20, HLA-A*68:02,
HLA-A*03:01, HLA-A*11:01, HLA-A*30:01, HLA-A*31:01, and HLA-A*68:01. Next, all data for alleles with a
distance (see above) of less than 0.2 to any of the alleles in this list were removed from the SA data. Finally, an SA
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model  was  trained  as  described  above  on  the  remaining  SA data,  and  MA model  on  the  remaining  SA data
combined with the complete MA data, respecting the original data partitioning.
Sequence motif construction
Sequence binding motif were visualized as Kullback-Leibler logo plots using Seg2Logo (50). Amino acids are 
grouped by negatively charged (red), positively charged (blue), polar (green) or hydrophobic (black). If not 
otherwise specified, binding motifs were generated from the top 0.1% of 200,000 random natural peptides (9mers 
for class I and 15mers for class II) as described earlier (14).
Binding motifs similarity comparison
The similarity between two HLA binding motifs  was  estimated in terms of the Pearson’s correlation
coefficient (PCC) between the two vectors of 9*20 elements (9 positions and 20 amino acid propensity
scores at each position). 
Model performance evaluation
For model comparison, the AUC (Area Under the ROC Curve) and AUC 0.1 (Area Under the ROC Curve integrated
up to a False Positive Rate of 10%) performance measures were used. For a given model, each test set was predicted
using the model trained during cross-validation. Next, all test sets were concatenated, and an AUC/AUC0.1 value
was calculated for each MHC molecule/cell line identifier. In case of multi-allele data, the prediction score to each
peptide was assigned as the maximal prediction value over the set of possible MHC molecules. 
To evaluate the “cleanness” of a given cluster/motif identified by NNAlign_MA, positive-predictive values (PPV)
were calculated. For each cell line, we calculated the number of ligands N predicted to be bound to each allele from
the concatenated test set predictions. Next, the PPV for each motif was calculated as the fraction of peptides in the
top N*0.95 predictions that were actual ligands. The values of 95% was selected to tolerate a certain proportion of
noise in the EL data (29).
In vitro binding data
Recombinnt BoLA-1*00901 and human beta-2 microglobulins (β2m) were produced as previously described (51).
In brief, biotinylated BoLA-1*00901 was generated in Escherichia coli, harvested as inclusion bodies, extracted into
Tris-buffered 8 M urea and purified using ion exchange, hydrophobic, and gel filtration chromatographies. MHC-I
heavy chain proteins were never exposed to reducing conditions, which allows for purification of highly active pre-
oxidized  BoLA  molecules,  which  folds  efficiently  when  diluted  into  an  appropriate  reaction  buffer.  The  pre-
oxidized, denatured proteins were stored at  −20 °C in Tris-buffered 8 M urea.  Human β2m was expressed and
purified as previously described (52). 
Nonameric peptide binding motifs were determined for BoLA-1*00901, using PSCPL as previously described (51,
53, 54). Recombinant, biotinylated BoLA heavy chain molecules in 8 M urea were diluted at least 100-fold into PBS
buffer  containing  125I-labeled  human  β2m  and  peptide  to  initiate  pMHC-I  complex  formation.  The  final
concentration of BoLA was between 10 and 100 nM, depending on the specific activity of the heavy chain. The
reactions were carried out in the wells of streptavidin-coated scintillation 384-well FlashPlate® PLUS microplates
(Perkin Elmer, Waltham, MA). Recombinant radiolabeled human β2m and saturating concentrations (10 μM) of
peptide were allowed to reach steady state by overnight incubation at 18 °C. After overnight incubation, excess
unlabeled bovine β2m was added to a final concentration of 1 μM and the temperature was raised to 37 °C to initiate
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dissociation.  pMHC-I  dissociation  was  monitored  for  24  h  by  consecutive  measurement  of  the  scintillation
microplate on a scintillation TopCount NXT multiplate counter (Perkin Elmer, Waltham, MA). PSCPL dissociation
data were analyzed as described33. Briefly, following background correction, the area under the dissociation curve
(AUC) was calculated for each sublibrary by summing the counts from 0 to 24 h. The relative contribution of each
residue in each position (i.e., the relative binding, RB) was calculated as RB=(AUC_sublibrary/AUC_X9). The RB
values were next normalized to sum to one for each peptide position and used as input to Seq2Logo to generate the
in vitro BoLA-1*00901 binding-motif.
Results 
A key issue associated with the interpretation and analysis of LC-MS MHC eluted ligand datasets (EL data) stems
from the  challenge  of  deconvoluting  and  linking  each  ligand back  to  the  presenting  MHC molecule(s)  of  the
investigated cell lines.  In the following, we describe  the NNAlign_MA framework resolving this challenge, and
showcase how the framework can be applied to effectively integrate MA EL data in a semi-supervised manner into
machine-learning models for improved prediction of MHC antigen presentation and T cell epitopes on the three
large datasets of human (class I and class II) and cattle MHC class I ligand and T cell epitope data.
The NNAlign_MA algorithm
The NNAlign_MA algorithm is an extension of the NNAlign neural network framework, and is capable of taking a 
mixed training set composed of single-allele data (SA, peptides assigned to single MHCs) and multi-allele data 
(MA, peptides that are assigned to multiple MHCs), and fully deconvolute the individual MHC restriction of all MA
peptides, learning the binding specificities of the MHCs present in the training set. In short, the NNAlign framework
underlying NetMHCpan-4.0 method, is an artificial neural network method integrating SA binding affinity and EL 
data with sequence information of the MHC molecules, allowing information to the leveraged both between data 
types and MHC data sets, resulting in pan-specific predictive power (14). 
The MA extension of NNAlign consists of various critical steps (see Figure 1 for a schematic overview). First, a
neural network is pre-trained on SA data only during a burn-in period, using the NNAlign framework. This results in
a pan-specific model with potential to infer binding specificities also for MHC molecules not included in the SA
dataset (14,  48). After this initial training period (from now on referred to as “pre-training”), the data in the MA
datasets are annotated. That is, binding for each positive peptide in the MA dataset is predicted (using the ligand
likelihood prediction value from the pre-trained model) to all the possible MHC molecules of the given cell line and
the restriction is inferred from the highest prediction value (for details see Materials and Methods). For negative MA
data, a random MHC molecule from the given cell line is tagged. Next, the SA and now single-MHC annotated MA
data are merged, and the model is retrained on the combined data. Note, that the MHC allele annotation is updated at
each iteration, and will in general change as the training progresses. Implicitly, the algorithm exploits the principles
of co-occurrence and exclusions outlined by Bassani-Sternberg et al. (28): i.e. sequence motifs that consistently
occur across multiple cell lines sharing only specific MHC alleles are assigned to the shared MHC(s) by the iterative
annotation step. For an illustration of this effect  refer for instance to HLA-B*13:02, the only allele in common
between the two cell lines CM467 and pat-NS2. The binding motif for this molecule (and the other HLA molecules
in each cell line) as obtained by NNAlign_MA are shown in Supplementary Figure 1. Here, it is apparent that only
one motif is shared by these two cell lines, and the co-occurrence principle allows NNAlign_MA to assign this motif
to  HLA-B*13:02.  In  ambiguous cases  where  co-occurrence  and exclusion principles  are  insufficient,  the pan-
specific  nature  of  the  method  will  help  tilt  the  annotation  towards  the  correct  MHC.  An  example  of  this  is
showcased by the motif of BoLA-1:00901 in Figure 1. BoLA-1:00901 is only present in the MA data, and hence are
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data for this molecule only presented to the model after the pre-training. Since no MHC molecule in the SA data
share a strong preference for H at P9, H at P9 is absent in the predicted motif for BoLA-1:00901 after pre-training.
After pre-training, the data from the two cell lines (A12/A15 and A15/A15) expressing BoLA-1:00901 are presented
to the model,  hence  for  the first  time showing peptides  with a  H at  P9.  NNAlign_MA is  now faced  with the
challenge of assigning these peptides to one or more of the alleles expressed in the two cell lines. The method does
this in two ways, by within each cell line predicting for each peptide binding to all expressed alleles and selecting
the most favorable as the potential restriction element, and by transferring knowledge of binding preferences for the
different alleles imposed by ligands in other cell line data sets. Analyzing the binding of peptides using the pre-
training model, BoLA-1:00901 (in contrast to BoLA-4:02401 and BoLA-2:02501) is found to tolerate H at P9 (the
H is not present in the motif since this motif only displays amino acid enrichments). Further, both BoLA-4:02401
and BoLA-2:02501 are expressed in a third cell line (A14), but none of the motifs identified here share a preference
for H at P9 (see Supplementary Figure 4). Taken together, these properties enable the model to assign peptides with
H at P9 to BoLA-1:00901. For details  on model hyper-parameters  and model training setup, see Materials and
Methods. 
HLA-I benchmark
To benchmark NNAlign_MA, we trained a model on the complete set of SA data described in the NetMHCpan-4.0
paper,  combined  with an extensive  set  of  MA data  covering  50 different  cell  lines  with typed HLA allotypes
described in Bassani-Sternberg et al. (28). Note that, prior to training, we removed all overlapping peptides between
the SA and MA data from the SA data set. This was done to fully demonstrate the power of the NNAlign_MA to
annotate MA data also in situations where the information cannot simply be transferred from the SA data. After
training, each MA data point ends up being annotated to a single MHC molecule,  and from this annotation the
distribution of ligands associated with each HLA molecules was recovered. Based on the predicted 9mer binding
cores of the ligands, logos for all the HLA alleles expressed by each of the cell lines under study was constructed
(Supplementary Figure 1). In this benchmark, NNAlign_MA was capable of not only clustering the EL data into a
set of groups matching the number of expressed HLA alleles in each cell line (this is guaranteed by the construction
of the method), but also to assign each group to a single corresponding HLA allele. As a point of comparison, on the
same benchmark data, MixMHCp was only capable of achieving a complete deconvolution of all HLA specificities
in 26% of the 50 cell line data sets (failing to identify motif corresponding to HLA-C alleles in 61% of the cases),
and could not annotate at least one cluster in 16% of the samples. Two examples of this are given in Figure 2,
showing the NNAlign_MA deconvolution of the two cell lines HCC1143 and HCT116. In the first case, MixMHCp
correctly identified 5 motifs, but could not assign two of the five to their corresponding allele (respectively HLA-
A*31:01 and HLA-B*37:01). For HCT116, MixMHCp was able to deconvolute and assign only four of the six
expressed alleles, missing the deconvolution of the motifs for two HLA-C alleles, HLA-C*05:01 and HLA-C*07:01.
The accuracy  of  the 4 motifs  additionally identified by NNAlign_MA was confirmed by reference  to SA data
available from IEDB (37) (see Figure 2). 
As stated above, the NNAlign_MA method by construction is guaranteed to cluster the MA data into a number of
groups matching the number of HLA alleles expressed in each cell line. The association of each cluster to the correct
HLA molecule, and the accuracy of each cluster are, however, not guaranteed. By investigating the deconvolution
solutions for the different cell lines (Supplementary Figure 1), it is apparent that the accuracy of the motifs identified
by NNAlign_MA (as expected) depends on the number of ligands assigned to a given HLA, and that complete
characterization of the HLA’s in a given cell line, for a few cases, is impeded by this fact (a few examples include
the motif for HLA-C*07:04 from Fibroblast, HLA-C*08:01 from Mel-624, and HLA-C*02:10 from RPMI8226).
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These are further examples of alleles only present in single MA data sets, limiting the ability of NNAlign_MA to
transfer information of the binding motifs from other data sets.  
To further quantify the accuracy of the cluster-HLA association, we compared the motifs obtained by NNAlign_MA
to the motifs obtained from SA data in situations where such data were available from the IEDB (Supplementary
Figure 2). Here,  we in the vast majority of cases observed an excellent  agreement,  with an average correlation
between the two motifs of 0.883 over the 46 alleles included (p-value for the correlation being random was in each
case  <  0.001,  exact  permutation  test,  for  details  on how the correlation  was  calculated  refer  to  Materials  and
Methods. Note, that this correlation was equally high for alleles characterized by SA EL training data and alleles not
characterized by SA EL data (average PCCs of 0.883 and 0.876, respectively). As expected, the agreement between
the MA and SA motifs also here was highest for the cases where both motifs were characterized by large data sets. 
Next, we compared the motifs of individual HLA alleles obtained across different cell lines, for example the HLA-
C*03:03 allele, shared between 5 cell lines. Using again a simple correlation analysis, we quantified the similarity of
these different motifs, and could in all cases confirm a high consistency, with an overall averaged correlation of
0.901 over the 17 alleles shared by 5 of more cell lines (Supplementary Figure 3). These correlation values were all
significantly different from random (p<0.0001, exact permutation test), and significantly higher than the correlations
obtained by comparing motifs assigned to different HLA molecules (p<10-5, T-test). Also, the correlations were
lowest for the comparison between motifs characterized by small data sets (as exemplified by the motifs for HLA-
C*07:02 from the HCC1937 and Mel-8 cell lines, each characterized by 48 and 31 ligand data points respectively
(see Supplementary Figure 1), resulting in a correlation between the two motifs of 0.68). Finally, we evaluated the
“cleanness” of each cluster/motif by calculating predicted positive (PPV) values. Here, all clustering solutions were
found to have very high accuracy, with an average PPV value of 75% (for details on the calculation of the PPV refer
to Materials and Methods, and for the complete list of PPV values refer to Supplementary Table 5. 
Taken together, these results demonstrate the high performance of NNAlign_MA, achieving in the vast majority of
cases an accurate, consistent and complete (including for HLA-C) deconvolution of MA EL data sets.
Given these encouraging results, we next conducted a full-scale performance evaluation for prediction of eluted
HLA ligands. To this end, we first compared the performance of NNAlign_MA trained on the complete HLA-I
dataset (referred to as the MA model) to the performance when trained only on the subset of SA data (referred to as
the SA model).  Note, that this SA model is trained identically to NetMHCpan-4.0, with the only exception of the
removal  of  overlapping  peptides  between  the  SA  and  MA described  above.  This  benchmark  (Figure  3A)
demonstrated that the MA model exhibited a consistently (and statistically significant,  p<0.0001, paired T test)
higher performance when evaluated on the MA data (median AUC of 0.9769), in comparison to the SA model
(median AUC of 0.9712). On the other hand, as expected, the MA and SA models showed an overall comparable
predictive performance when evaluated on the SA data (median AUC of 0.9842 versus 0.9839). We hypothesized
that NNAlign_MA would demonstrate a performance gain over NNAlign_SA for alleles where the SA data are
either limited or absent. The results displayed in Figure 3 confirmed this. Here, the median number of positives for
SA data sets where NNAlign_MA outperforms NNAlign_SA was 57 whereas the number for the SA data sets where
NNAlign_SA won was 435. Further, was the performance gain of NNAlign_MA on the MA data found to be largest
for  data  sets  characterized  by alleles  absent  from the  SA data.  Lastly,  we  investigated  if  the  MA model  also
demonstrated improved performance compared to the SA model for binding affinity (BA) predictions. Here, we
evaluated the performance of the two models in terms of  the allele specific  PCC on the BA data using cross-
validation. Also, here did the MA significantly outperform the SA model with median PCC values of 0.766 and
0.759 (p<0.005, binominal test).
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Next, we investigated how the peptidome for the MA EL data in each dataset was distributed among the alleles of
the  three  loci  HLA-A,  HLA-B  and  HLA-C.  To  do  this,  we  extracted  the  number  of  ligands  predicted  by
NNAlign_MA to be restricted by HLA-A, HLA-B and HLA-C for each cell line present in the MA EL dataset and
then calculated the proportion of ligands associated to a given loci relative to the total amount of peptides in the cell
line. The result of this analysis is shown in Figure 3B, and confirms the general notion that HLA-A and HLA-B
have comparable peptidome repertoire size, whereas the peptidome size of HLA-C, in comparison, is substantially
reduced (53).  While this is not a novel observation, to the best of our knowledge this is the first fully automated
analysis of EL data demonstrating this.  Some clear outliers are present in the figure where either the HLA-A or
HLA-B peptidome repertoires are highly reduced compared to the median values. A few such examples include the
HL-60, CA46, Mel-624 and HEK293 cell lines where either the entire HLA-A or HLA-B locus appears to have been
deleted or made non-functional. These observations are in agreement with results from earlier studies for these cell
lines (for details refer to Supplementary Table 6), suggesting the power of NNAlign_MA also for identification of
loss or down-regulation of HLA expression directly from EL datasets.
Evaluation on HLA-I epitopes from IEDB
To further investigate the predictive power of NNAlign_MA, we employed an evaluation set of epitopes of length 8-
14 extracted from IEDB (see Materials and Methods for details). Here, we divided the dataset into two subsets; one
containing the epitopes restricted to HLAs that were part of the SA training dataset, and one where the HLAs were
not present in the SA training data. The results of the evaluation on these two datasets for the SA and MA models,
and the state-of-the-art method NetMHCpan-4.0 are shown in Figure 3C in terms of Frank values. This measure
reflects the false-positive rate, and a value of 0 corresponds to the perfect prediction (for details see Materials and
Methods). For epitopes restricted to HLA molecules that are part of the SA dataset (red points), the figure displays a
comparable performance of the MA and NetMHCpan-4.0 methods (median Frank values 0.0021 and 0.0020, p=0.3,
paired T test), and a significantly worse performance of the SA method (median Frank 0.0022, p<0.0025 paired T
test). Further, when evaluated on the small set of epitopes whose HLA restrictions are only present in the MA data
(blue  points),  the  performance  of  the  MA  model  is  substantially  increased  compared  to  both  the  SA  and
NetMHCpan-4.0 models (average Frank of 0.0091 compared to 0.0186 and 0.0166 for the SA and NetMHCpan
models).  These  results  demonstrate  how the  NNAlign_MA model  also  when  it  comes  to  prediction  of  T  cell
epitopes achieved state-of-the-art performance, and further is capable of benefiting from MA data to expand the
allelic coverage outside SA data set to improve the allelic coverage and predictive power.
Finally, in figure 3D, the evaluation was expanded to include the MHCFlurry (trained without and with EL data) and
MixMHCpred  methods  limiting  the  benchmark  to  include  only  HLA molecules  covered  by  all  methods,  thus
including only HLA alleles with previously well-characterized binding motifs (for details on the benchmark refer to
Materials  and Methods).  The results of this benchmark confirmed a comparable performance of NNAlign_MA
(median Frank 0.0021) to NetMHCpan-4.0 (median Frank 0.0021), and a small (but statistically significant, p<0.05
paired  T-test,  in  all  cases  except  for  MHCFlurry)  drop in  performance of  MHCFlurry (median Frank 0.0031),
MHCFlurry_EL (median Frank 0.0033), MixMHCpred (median Frank 0.0023) and NNAlign_SA (median Frank
0.0024). This result confirms the state-of-the-art performance of NNAlign_MA.
A specificity leave-out benchmark
All the benchmarks performed hereto were conducted in situations where the MA data shared high HLA overlap
with the SA data. By way of example, over 75% (51 of 67) of the alleles in the MA dataset were part of the SA data,
and 94% (63 of 67) share a distance of less than 0.1 to an allele in the SA data as measured from the similarity
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between pseudo sequences (for details on this similarity measure see Materials and Methods), a distance threshold
earlier demonstrated to be associated with high predictive accuracy of the pan-specific prediction model (55). 
As stated above and confirmed by the results in Fig 3A and 3C, the main power of NNAlign_MA is to effectively
extend the allele-space covered by HLA annotated EL data leading to an improved predictive power outside the
space covered by SA data. Given the high allelic overlap between the MA and SA data set, it is hence not surprising
that the impact of including MA data in these benchmarks was limited. Therefore, to further test the power of the
NNAlign_MA method in a more extreme setting, we conducted an experiment where parts of the SA data were left
out from the training data leaving part of the HLA space covered only by MA data. In short, we removed all SA data
for HLA molecules belonging to (or similar to alleles in) the HLA-A2 and HLA-A3 supertypes (49), effectively
pruning off whole branches from the tree of HLA specificities (Figure 4 left panel) (for details on this pruning refer
to  Materials  and  Methods).  This  scenario  thus  simulates  a  situation  where  the  MA  data  describes  binding
specificities that a novel compared to any specificity contained in SA training data.  Given this, the binding motifs in
the MA data cannot  simply be  inferred  from a close neighbor in  the SA data,  making the  challenge  of  HLA
deconvolution non-trivial. This experiment therefore allows us to investigate how the NNAlign_MA method can
benefit from MA data to accurately characterize the binding specificity of HLA molecule not characterized by SA
data, and from such MA data expand the HLA coverage of the trained prediction model. 
In the benchmark, SA and MA models were trained as described above on the pruned SA and complete MA data,
and the predictive performance was evaluated on SA EL data for the alleles on the pruned branch. Note, that this
evaluation was done respecting the data partitioning of the cross validation to avoid introducing a bias in favor of the
MA model. The performance was estimated in terms of AUC0.1 resulting in average values of 0.599 versus 0.852
for the SA and MA models respectively (for details on the performance values see Supplementary Table 7). 
Next, binding motifs for the alleles in the MA data from the A2 and A3 supertypes were estimated for the MA and
SA models and compared to motifs derived from SA EL data if available (see Figure 4 right panel).  Here,  we
observed a high overlap between the motifs of the MA model motifs obtained from SA EL data, and a likewise low
overlap of the motifs obtained by the SA model. Note, also here that the agreement between the MA model and SA
EL data motifs was dependent on the number of ligands assigned to the given allele from the MA data, i.e. HLA-
A*02:01 was assigned 26,038 and HLA-A*02:05 only 917 ligands from the MA data resulting in a somewhat lower
agreement between the two motifs for HLA-A*02:05 compared for HLA-A*02:01. Finally, we reinvestigated the
performance of the SA and MA models trained on the pruned SA data set, on the subset of 358 epitopes restricted by
the 11 alleles covered by the two A2 and A3 supertypes. This benchmark confirmed the superior performance of the
MA model over the SA model with median Frank values of 0.0044 compared to 0.0393 (p<10-15, paired T test).
Note,  the performance of the full MA model on this epitope data set  was 0.0032. Taken together  these results
demonstrate the power of the NNAlign_MA to accurately characterize individual binding motifs of molecules from
MA data only. 
BoLA-I benchmark
Having demonstrated how NNAlign_MA was capable of benefitting from MA EL data to boost predictive power
and expand the allelic coverage also in a setting where the MA data shared limited allelic overlap to the SA data, we
next turned to the BoLA (Bovine Leukocyte Antigen) system. Because binding data (both BA and EL) is more
scarce for BoLA compared to HLA, and because the relative expression of MHC molecules within a given cell line
varies in a more dramatic manner for the bovine system compared to humans, analyzing and deconvoluting BoLA
MA EL data is more challenging compared to HLA, and working within this system allowed us to better appreciate
and assess the strength and potential limitations of the NNAlign_MA framework.
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In a previous work, a prediction model for BoLA peptide interactions, NetBoLApan, was trained using NNAlign on
SA BA (including binding affinity data for 7 BoLA molecules) and EL MA data from 3 BoLA-I homozygous cell
lines,  describing  the  BoLA haplotypes  A10,  A14,  and  A18 (16).  Due  to  the  prior  limitation  of  the  NNAlign
framework only admitting SA data for training, in NetBoLApan the EL MA data had to be first deconvoluted using
GibbsCluster and then manually annotated to the individual BoLA molecules of each cell line by visual inspection.
Since this earlier publication, we have generated MA EL data for additional 5 cell lines. Using these data, we trained
and evaluated the NNAlign_MA framework on the SA data described above combined with EL MA data for a total
of 8 BoLA cell lines (for details on these datasets, refer to Materials and Methods and Supplementary Table 4).
After training, we proceeded to investigate the different binding motifs captured by the model. In particular, we
were interested in the motifs of the BoLA molecules shared between multiple haplotypes. One such example is
BoLA-2*02501, present in the A14, and A15 haplotypes. While the motif for this molecule in our earlier work
showed a strong preference for G/Q and L at P2 and P9 respectively (Figure 5B), the new NNAlign framework
captured a completely different signal, with a consistent proline (P) signal on most positions (see Figure 5A). Also,
the  number  of  ligands  assigned  to  BoLA-2*02501 was  extremely  low for  the  three  cell  lines  expressing  this
molecule (less than 1.5% in all three cases). A prime source of this result is the very large distance (0.426) of BoLA-
2*02501 to the SA training data (for details on this distance measure refer to section “Distance between pairs of
MHC molecules” above). In comparison, the maximum distance between any molecule in the MA data to the SA
training data for the HLA system is less than 0.13. These large pairwise distances in the BoLA system have two
strong impacts on the predictive behavior of NNAlign_MA. First and foremost, the model pre-trained on the SA is
expected to have limited power to predict the binding motif of the BoLA-2*02501 molecule (in the pre-trained
model, BoLA-2*02501 has a preference for P at P2). Secondly, the prediction values of the pre-trained model will
be lower for this molecule compared to molecules that share higher similarity to the SA data used for pre-training.
To deal  with the latter of these two issues,  we devised a rescaling scheme for the prediction score in the MA
annotation  step  of  the  NNAlign_MA framework,  and  rescaled  the  raw prediction  by  comparing  it  to  a  score
distribution obtained from a large set of random natural peptides (for details refer to the “Prediction score rescaling”
section in materials and methods). This score distribution was recalculated in each training iteration prior to the MA
annotation. Including this rescaling step, the number of ligands estimated by cross-validation to be assigned to
BoLA-2*02501 from the three cell lines increased to 13% on average. 
However, investigating the motifs from the ligands predicted to be associated with BoLA-2*02501 from the A14
MA data to that from A12/A15 and A15 MA data, an inconsistency became apparent (see Figure 5C and D). Here,
the motif obtained from the A14 MA data showed an additional preference for G at P2 that was completely absent
for the motif obtained from the A15 and A12/A15 MA data.  Re-examining the original publication that described
the  BoLA  allele  expression  profile  in  the  A14  haplotype  (56),  suggested  an  explanation  to  the  apparent
inconsistencies in the predicted BoLA-2*02501 binding motifs. In that paper, A14 was found to express 4 and not 3
BoLA alleles, as was assumed in our earlier publication and used in the first NNAlign_MA analysis. The extra allele
expressed is BoLA-6*04001. After including this extra allele in the A14 haplotype and retraining the model, we
obtained the binding motifs displayed in Figure 5E, showing a motif for BoLA-2*02501 consistent with the motif
identified in the A12/A15 and A15 MA  data (Figure 5D), and a likewise well-defined motif for BoLA-6*04001
(Figure 5F).  These results clearly suggest  that  the motif earlier  reported for BoLA-2*02501 (Figure 5B)  was a
mixture of the motifs of BoLA-2*02501 and BoLA-6*04001.
The benchmark on the BoLA EL data confirmed the power of the NNAlign_MA method to achieve complete,
consistent and well-defined deconvolution and motif identification of MHC alleles in the MA EL data sets, also in
this challenging case with limited overlap between the SA and MA data (for details on the deconvolution refer to
Supplementary Figure 4).  One notable example demonstrating this is BoLA-1:00901, a molecule contained within
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the  A15 haplotype.  BoLA-1:00901 shares  limited  overlap  with  the  SA training  data  (distance  to  the  SA data
D=0.137),  and the motif predicted by the NNAlign_MA method after the pre-training on the SA data share,  as
expected,  high similarity to the motif predicted by NetBoLApan (Figure 6).  This pre-trained motif is, however,
altered substantially after the training of the model on the EL MA BoLA data, resulting in a strong preference for
Histidine (H) at PΩ (Post-training motif in Figure 6). To validate the accuracy of the motif predicted for BoLA-
1:00901, we performed  in vitro binding assays of a combinatorial peptide library to the BoLA-1:00901 molecule
(for details see Materials and Methods). The in vitro binding motif showed very high similarity to the Post-training
motif predicted by NNAlign_MA (Figure 6). 
Evaluation on BoLA-I epitopes
Having demonstrated the power of the proposed model also for the challenging BoLA system, we next evaluated its
predictive power on a set of experimentally validated BoLA restricted CD8 epitopes. The result of this evaluation
for NNAlign_MA and NetBoLApan confirmed the high performance of the proposed model (Table 2). Overall, the
performance of the NNAlign_MA model is comparable to that of NetBoLApan. However,  one notable example
where  the  two models  showed  very  different  performance  is  the  FVEGEAASH  epitope,  restricted  by  BoLA-
1:00901. For this epitope, the Frank performance value of NetBoLApan was 0.121 - in other words, the true positive
is found 12.1% down the list of candidate peptides predicted by NetBoLApan. Including the novel BoLA EL data
and training the model using the NNAlign_MA framework, the Frank value for this epitope improved to 0.000 - the
epitope is the single top candidate predicted by NNAlign_MA. This result aligns with the experimental  binding
motif analysis of the BoLA-1:00901 molecule, exhibiting a strong preference for H at the C terminal (Figure 6). In
summary, the results displayed in Table 2 demonstrate the high predictive power of the model trained including the
BoLA EL data also for prediction of CD8 epitopes. The average Frank value of NNAlign_MA over the 16 epitopes
is 0.0033, meaning that on average 99.67% of the irrelevant peptide space can be excluded by the prediction model
while still identifying 100% of the epitopes. 
Table 2. Predictive performance of NNAlign_MA and NetBoLApan on the set of known CD8 epitopes.
Allele Epitope Antigen Npep NetBoLApan NNAlign_MA
T.
 p
ar
va
BoLA-6*01301 VGYPKVKEEML Tp1 2138 0.0098 0.0070
BoLA-6*04101 EELKKLGML Tp2 662 0.0000 0.0000
BoLA-2*01201 SSHGMGKVGK Tp2 662 0.0060 0.0045
BoLA-T2c FAQSLVCVL Tp2 662 0.0136 0.0151
BoLA-2*01201 QSLVCVLMK Tp2 662 0.0015 0.0015
BoLA-AW10 TGASIQTTL Tp4 2282 0.0000 0.0000
BoLA-1*00902 SKADVIAKY Tp5 586 0.0000 0.0000
BoLA-T7 FISFPISL Tp7 2850 0.0172 0.0112
BoLA-3*00101 CGAELNHFL Tp8 1726 0.0029 0.0035
BoLA-1*02301 AKFPGMKKS Tp9 1302 0.0054 0.0023
B
H
V
BoLA-1:00901 FVEGEAASH ICP4 5350 0.1215 0.0000
BoLA-3:00201 AGPDLQLARL ICP4 5350 0.0000 0.0000
BoLA-3:00201 TTPEILIEL Circ 1006 0.0000 0.0000
BoLA-3:01701 TGARAGYAA ICP4 5350 0.0350 0.0013
BoLA-4:02401 GAFCPEDW ICP22 1214 0.0066 0.0058
BoLA-2:01801 APAPSPGAL Circ 978 0.0020 0.0000
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Average 0.0138 0.0033
Performance values for NetBoLApan and NNAlign_MA are reported as Frank. In short, we predicted binding for all overlapping 
8−11mer peptides from the source protein of the epitopes to the known BoLA-I restriction molecule. Then, the performance for 
each epitope was reported as the Frank score. Epitope data for Theilera parva (T. parva) and Bovine Herpes Virus (BHV) were 
obtained from three sources (16, 57, 58). The lowest Frank value for each epitope is highlighted in bold.
HLA-II benchmark
To prove that the ability of NNAlign_MA to deal with MA data also extended to MHC II, a separate study was
conducted  on  a  set  of  MHC  II  BA  and  EL  data.  Here,  we  compared  the  cross-validated  performance  of
NNAlign_MA trained on SA data alone (SA model) versus NNAlign_MA trained on the full dataset including MA
data (MA model). Both models were evaluated individually on the SA and MA data sets as described earlier for the
HLA-I benchmark. The conclusions from this evaluation (Figure 7A) were similar to those obtained for the HLA-I
data: when evaluated on SA data, the SA model demonstrated a modest (and statistically insignificant (p=0.125,
binomial test) performance gain compared to the MA model. However, when it comes to the MA data, the MA
model  significantly outperformed the SA model (p=7.6  * 10-6,  binomial  test  excluding ties).  In  Supplementary
Figure 5, we further show the binding motifs for MA data included in this study demonstrating that also for class II
is the NNAlign_MA framework in the vast majority of cases capable of achieving clear and consistent MHC motif
deconvolution. However, as for the class I data does the accuracy of the motifs identified by NNAlign_MA also here
depend on the number of ligands assigned to a given HLA. For example, is the motif for HLA-DRB1*13:01 most
often derived from a very small number of ligands resulting in a limited similarity between the motifs obtained from
the different MA data sets. This observation underlines the critical dependency of NNAlign_MA on the quality of
the input data. 
Next, we evaluated the performance of the SA and MA models together with NetMHCIIpan-3.2 on an independent
data set of CD4+ epitopes (for details on this data set refer to Materials and Methods. The results of this benchmark
are depicted in Figure 7B in terms of Frank values.  Here,  the median Frank values were respectively 0.02403,
0.03155, and 0.03734 for the three methods MA, SA and NetMHCIIpan-3.2. The difference in Frank between the
MA and  the  two  other  methods  was  in  both  cases  found to  be  statistically  significant  (p<0.01,  binomial  test
excluding ties). These results strongly suggest that the NNAlign_MA framework extends its predictive power also
into MHC class II.
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Discussion 
Advances in Mass Spectrometry have dramatically increased the throughput of immunopeptidomics experiments,
with several thousands of peptides directly eluted from their cognate MHC molecule in a single experiment. This
type of data has greatly changed our knowledge base for characterizing MHC antigen processing and presentation.
In general,  MS eluted ligands originate from multiple MHC molecules,  and MS datasets therefore consist  of a
mixture of motifs, each corresponding to the binding specificity of one of the MHC molecules expressed by the cell
line. While several tools for the deconvolution of multiple motifs have been proposed, they all tend to underestimate
the number of specificities in a sample, especially for haplotypes with overlapping MHC binding motifs and for
alleles with low protein expression. Even for peptidomes that can be confidently deconvoluted, the pairing between
motifs and the expressed MHC alleles is often not trivial, and in many cases must be done manually by visual
inspection – with the potential sources of error this process entails.
Here,  we  have  described  a  fully  automated  approach,  NNAlign_MA, aiming to  resolve  these  challenges.  The
approach taken in NNAlign_MA is very simple. The method applies a pre-training period where only single allele
data (peptide data characterized by having a single MHC association) are included. After this pre-training, the multi-
allele data (peptide data characterized by having two or more MHC associations) are annotated using the current
prediction model to predict binding to all MHC molecules possible for the peptide, and next defining a single MHC
association from the highest prediction value. In this annotation step, multi-allele data are thus casted into a single-
allele format, becoming manageable by the NNAlign method and therefore enabled for training. This multi-allele
annotation step is iteratively performed in each training cycle.
We have applied the NNAlign_MA method to analyze and interpret  three  large-scale  multi-allele  MHC eluted
ligand datasets, and demonstrated its unprecedented performance compared to state-of-the-art methods. First, we
applied the method to analyze multi-allele HLA MS eluted ligand data from 50 cell lines.  Using this data,  we
demonstrated how the method in the vast majority of cases was capable of correctly identifying distinct binding
motifs for each of the HLA molecules expressed in a given cell line. This result is in contrast to findings using
earlier methods such as GibbsCluster and MixMHCp that in most cases fail to identify one or more motifs. Also,
NNAlign_MA was in close to all cases capable of accurately associating each identified motif with a specific HLA
molecule.  These results highlighted the high performance of NNAlign_MA compared to current  state-of-the-art
methods such as MixMHCp/MixMHCpred, where the association of binding motifs to individual HLA molecules is
achieved by exclusion principles identifying binding motifs shared uniquely between different cell line datasets. 
In terms of predictive performance, the models trained using the NNAlign_MA method were found to outperform
conventional  methods  (trained  on  single-allele  data),  both  for  prediction  of  HLA eluted  ligand data  and  CD8
epitopes.  As  expected,  this  performance  gain  was  most  pronounced  for  ligands/epitopes  restricted  by  HLA
molecules characterized by limited or no single-allele data. This observation underlines the single most important
power of NNAlign_MA, namely to effectively expand the part of the HLA space covered by accurate predictions.
By  way  of  example,  the  SA EL data  included  in  this  study  covers  51  HLA molecules.  Earlier  studies  have
demonstrated that pan-specific prediction methods allow to accurately predict the binding specificity also for HLA
molecules not characterized by binding data, if their distance to a molecule characterized by binding data is 0.1 or
less (for a definition of this distance refer to Materials and Methods) (55). Applying this rule to the set of 10,558
functional HLA class I A, B and C alleles contained within IPD-IMGT/HLA release 3.35 (59) results in a coverage
of 76% (8,051 out of 10,558 molecules). By integrating the MA data, the number of alleles covered by EL data is
expanded to 85, and number of HLA molecules covered by accurate predictions to 94% (9,949 of 10,558 molecule).
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This power of NNAlign_MA to expand the allelic coverage was further demonstrated in a specificity leave-out
experiment. Here, entire HLA specificity groups were removed from the single-allele dataset, and the NNAlign_MA
framework applied to analyze and characterize  multi-allele  data including HLA molecules  from these removed
specificity  groups.  The  result  of  this  experiment  confirmed  the  power  of  NNAlign_MA to  expand  the  allelic
coverage  and  accurately  identifying  binding  motifs  for  individual  HLA molecules  in  multi-allele  data,  also  in
situations where no explicit information about the binding preferences of the investigated molecules was part of the
single-allele training data.
The HLA system has been studied in great detail over the past decades, and peptide-MHC binding data are available
for hundreds of alleles. To further explore the predictive power of NNAlign_MA for MHC systems characterized by
limited data, we turned to the Bovine Leukocyte Antigen (BoLA) system, and applied NNAlign_MA to analyze MS
MHC eluted  ligands  datasets  from 8  cell  lines  expressing  a  total  of  8  haplotypes  covering  16  distinct  BoLA
molecules.  These BoLA molecules shared,  for most parts,  very low similarity to the molecules included in the
single-allele data. Also in this setting, NNAlign_MA was demonstrated to accurately identify binding motifs in all
BoLA datasets, and the model trained on the BoLA MA data demonstrated a high predictive power for identification
of known BoLA restricted CD8 epitopes, identifying the epitopes within the top 0.3% of the peptides within the
epitope  source  protein  sequence.  These  results  thus  further  demonstrated  how  NNAlign_MA  was  capable  of
correctly deconvoluting binding motifs present in multi-allele data in situations with limited shared similarity to the
single-allele data. 
As a final validation, the NNAlign_MA framework was applied to MS EL data from MHC II. Also here, the models
were evaluated in cross-validation and on an independent set of CD4+ epitopes and the results were in agreement
with the results obtained for MHC I. That is, the model trained including MA data showed significantly improved
performance compared to models trained on SA data only, when evaluated on both MA EL data and CD4 epitopes.
In a recent work, Bulik-Sullivan et al. (60) have suggested an alternative approach to deconvolute and train MHC
antigen presentation prediction models using an allele-specific architecture, thus limiting the predictive coverage of
the model to MHC alleles present in the training data. This is in contrast to the architecture of NNAlign_MA, which
enables pan-specific predictions covering alleles outside the training data (as described above). Also, the allele-
specific nature of the method proposed by Bulik-Sullivan et al. limits the power of the tool to identify motifs and
construct prediction models for the alleles included in the training data. By way of example in the data presented by
Bulik-Sullivan et al., less than 65% of the alleles in their training set ended up covered by a prediction model. Future
work and independent benchmarking will allow us to evaluate which of the two approaches is optimal for a given
epitope discovery setting.
We have demonstrated how NNAlign_MA achieves  binding motif  deconvolution driven by similarity  to  MHC
molecules  characterized  by  single-specificity  data,  and  by  principles  of  co-occurrence  and  exclusion  of  MHC
molecules  between  different  poly-specificity  MS  eluted  ligand  dataset.  The  NNAlign_MA  failed  to  construct
accurate binding motifs for a few limited HLA molecules. These cases were all characterize by very few ligand data,
and by alleles only present in single MA data sets. This observation, combined with the power of NNAlign_MA to
expand the allelic coverage of the resulting prediction model, points to a direct application to effectively achieve
broad  and high  accuracy  allelic  coverage  for  regions  of  the MHC repertoire  with yet  uncharacterized  binding
specificities. Guided by NNAlign_MA, sets of cell lines with characterized HLA expression should be selected for
LC-MS/MS to maximize allele co-occurrence, allele exclusion and allele similarities with the comprehensive set of
available EL data so that the NNAlign_MA motif deconvolution for the uncharacterized binding specificities can be
achieved in an optimal manner. We believe this approach for generating additional MA data to be a highly effective
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manner to further improve prediction of MHC antigen presentation, moving beyond the limitations associated with
fulfilling this task using artificial single allele MS setups.
While peptide-MHC binding is arguably the most selective step in the MHC antigen presentation pathway, other
properties  contribute  to  determining  immunogenicity  of  T cell  epitopes.  The above mentioned work  by Bulik-
Sullivan et  al.  (60),  attempted to incorporate  gene  expression levels  and proteasome cleavage preferences  in a
machine-learning model, showing promising improvements for the prediction of cancer neo-epitopes. For the MHC
class  II  system,  consistent  signatures  of  peptide  trimming and processing  have  been  detected,  with  pioneering
attempts  to  incorporate  them  in  T  cell  epitope  prediction  models  (13,  61).  In  future  developments  of  the
NNAlign_MA framework, the effect on the predictive power of incorporating such additional potential correlates of
immunogenicity will be investigated.
Overall,  we  have  evaluated  the  proposed  NNAlign_MA  framework  on  a  large  and  diverse  set  of  data,  and
demonstrated how the method in all cases was capable of achieving a complete deconvolution of binding motifs
contained  within  poly-specific  MS  eluted  ligand  data,  and  how  the  complete  deconvolution  enabled  training
prediction models with expanded HLA allelic coverage for accurate identification of both eluted ligands and T cell
epitopes. In conclusion, we believe NNAlign_MA offers a universal solution to the challenge of analyzing large-
scale MHC peptidomics datasets and consequently affords an optimal way of exploiting the information contained in
such data for improving prediction of MHC binding and antigen presentation. The modeling framework is readily
extendable to include peptides with post-translational  modifications  (15,  62), and signals from antigen processing
located outside the sequence of the ligands (13). Given its very high flexibility, we expect NNAlign_MA to serve as
an effective tool to further our understanding of the rules for MHC antigen presentation, as a guide for improved T
cell epitope discovery and as an aid for effective development of T cell therapeutics.
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Figures & captions
Figure 1. Full NNAlign_MA framework. Initially, a model is pre-trained using SA data only (“NNAlign 2.0 Training” box); next,
MA data are annotated and merged with the SA data (“NNAlign 2.0 MA Annotation” box), generating newly annotated MA
data; then,  the training is repeated iteratively using such new data.  The NNAlign_MA algorithm encompasses all  the steps
indicated in the flow chart. It is important to notice that, for alleles that are part of one or more MA data sets, a prediction score
rescaling is applied in every epoch (iteration) after the pre-training, as a part of the MA annotation step. In the upper left part are
displayed examples of binding motifs of two MHC molecules just after pre-training (i=20). In the lower part of the figure are
shown the changes to predicted binding motifs of the same two MHC molecules as NNAlign_MA iterates over the data. Here “i”
refers to the number of iterations.
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Figure  2.  Sequence  clustering  and  labeling  comparison  between  NNAlign_MA.  MixMHCp  and  NetMHCpan-4.0  for  the
HCC1143 and HCT116 cell lines. Motifs corresponding to NNAlign_MA were constructed based on ligands from the given MA
data  set  (cell  line)  predicted  using  cross-validation  to  be  restricted  by  the  given  HLA molecule;  the  quantity  of  peptides
associated to each HLA molecule is given on top of the corresponding logos; allele annotation was performed automatically by
NNAlign_MA. MixMHCp motifs were constructed by running the algorithm on the ligands associated to each cell line; allele
annotation was obtained from (28). SA EL data motifs were derived from single-allele (SA) data available from the IEDB (37). 
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Figure 3. Benchmark of the prediction method on the HLA-I data. A) Performance of the SA and MA trained models on the SA
EL and MA EL data sets, expressed in terms of AUC. Each point corresponds to one SA or MA data set. SA data corresponds to
55 single-allele EL dataset.  MA data consist of EL data from 50 different cell  lines, each expressing more than one MHC
molecule.  To  evaluate  the  MA data,  each  data  point  was  assigned  the  highest  prediction  value  across  all  possible  MHC
restrictions in the given cell line dataset (for further details, see Materials and Methods). Performance values for the SA model on
the SA data sets, and for the MA model on the SA and MA data, were extracted from the cross-validated predictive performance.
B) The relative peptidome size for the three loci (HLA-A, HLA-B and HLA-C) as predicted by NNAlign_MA for the different
MA datasets. Each data point gives the relative proportion of ligands in each MA dataset predicted to be restricted by a HLA
from the given locus. The HLA restriction for each ligand data was estimated from the evaluation performance of the cross-
validation as described in Material  and Methods.  Only datasets where HLA expression is annotated for all  three loci were
included. C) Frank values for the epitope evaluation dataset for NetMHCpan-4.0 and models trained with only SA data (SA
Model) and with SA and MA data (MA Model). Red dots correspond to epitopes restricted to HLAs that were part of the SA
training data, while blue points refer to Frank values for epitopes with HLA restrictions absent from the SA training set. For
visualization, Frank values of 0 are displayed with a value of 0.00004. HLAs in the category "Alleles absent from SA data" are
HLA-B*13:02,  HLA-B*55:01  and  HLA-C*01:02.  D)  Frank  values  for  the  epitope  evaluation  on  NetMHCpan-4.0,
MixMHCpred, MHCFlurry (trained on BA data), MHCFlurry_EL (trained on BA and EL data) and the models trained with only
SA data (SA Model) and MA data (MA Model). For visualization, Frank values of 0 are displayed with a value of 0.00004.
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Figure 4.  HLA supertype pruning experiment.  The left  panel shows a functional  tree  of  HLA specificities estimated using
MHCcluster (63). Branches in light blue and red correspond to the A2 and A3 HLA supertypes. In the HLA supertype tree
pruning experiment, SA data for HLA molecules belonging to both these branches were removed. Right panel shows binding
motifs for A2 and A3 supertype alleles from the MA EL dataset predicted by the MA and SA models. Motifs were constructed
from the top 1% of 1,000,000 random natural 9mer peptides predicted by each model. SA EL data show motifs derived from SA
EL data (not included in the training). For alleles marked with * no SA EL data was available and motifs were obtained from
NetMHCpan from http://www.cbs.dtu.dk/services/NetMHCpan/logos_ps.php.
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Figure 5.  Identification of binding motifs for the BoLA-2*02501 molecule A) Binding preference for this molecule found by the
NNAlign_MA method without score rescaling, B) motif logo found in our previous work (16). The top five repeating binding
cores present in each motif alignment are shown below each logo.  Binding motifs for BoLA-2*02501 obtained by NNAlign_MA
trained including three BoLA alleles (BoLA-1*02301, BoLA-4*02401, and BoLA-2*02501) for the A14 MA data from ligands
predicted using cross-validation to be restricted by BoLA-2*02501 from the A14 MA data (C), and from the A15 and A12/15
MA datasets (D). Binding motifs for the BoLA-2*02501 (E) and BoLA-6*04001 (F) molecules as estimated from ligands in the
A14 MA data as predicted by NNAlign_MA using cross-validation when expanding the list of alleles in A14 to include BoLA-
6*04001.
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Figure 6. Binding motifs for the BoLA-1*00901 molecule estimated by different in silico and in vitro binding methods. Binding
motifs  for  the three  in  silico methods were estimated from the top 0.1% of  1,000,000 random natural  9mer peptides  with
predicted binding by the given method, for BoLA-1:00901. The in vitro binding motifs were estimated using a position scanning
combinatorial peptide library, as described in Materials and Methods. The three in silico methods are: NetBoLApan (16), trained
including EL data for the cell lines A10, A14 and A18; Pre-training, the NNAlign_MA method pre-trained on SA data; Post-
training, the NNAlign_MA method after completing the training including MA data.
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Figure 7. Method benchmarking on HLA class II data. A) Performance of NNAlign_MA trained on SA and MA data evaluated in
cross-validation. Model performance is given in terms of AUC and calculated as described in Figure 3. Each point refers to an
individual SA or MA data set. B) Epitope Frank scores of NetMHCIIpan-3.2 and NNAlign_MA trained on SA and MA data
evaluated on CD4+ epitopes from the IEDB (37). The plot compares the Frank distribution of the MA and SA models and each
point represents the Frank of an epitope. For visualization, Frank values of 0 are displayed with a value of 0.0008.
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